Migrastatin is primarily studied for its potential applications in cancer treatment, particularly in inhibiting cancer cell migration and metastasis. It has shown promise in reducing the spread of certain types of cancer cells, such as breast and lung cancer, by targeting specific cellular mechanisms involved in motility. Researchers are exploring its use as a lead compound in developing anti-metastatic drugs, which could complement existing therapies by preventing the progression of cancer to other parts of the body. Additionally, migrastatin's ability to interfere with actin polymerization makes it a valuable tool in studying cell movement and cytoskeleton dynamics in biomedical research. Its applications remain largely in the experimental and preclinical stages, with ongoing studies aimed at optimizing its efficacy and safety for potential therapeutic use.